Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Amarin Corporation PLC (AMRN : NSDQ)
 
 • Company Description   
Amarin Corporation plc is a commercial-stage pharmaceutical company focused on developing therapies, especially based on omega-3 fatty acid for treating cardiovascular diseases. The company's sole marketed drug, Vascepa (icosapent ethyl) is approved in the United States as an adjunct to diet for treating severe hypertriglyceridemia or elevated triglyceride levels. The FDA approved Vascepa to reduce cardiovascular risk in patients with persistent elevated triglycerides on statin therapy for LDL-C. The drug received approval for both indications in Europe under the tradename of Vazkepa. It has initiated various promotional activities and direct-to-consumer programs as well as expanded its salesforce to support promotion of Vascepa's expanded label. A generic version of Vascepa has been launched for elevated TG levels.

Number of Employees: 560

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.42 Daily Weekly Monthly
20 Day Moving Average: 7,376,649 shares
Shares Outstanding: 396.54 (millions)
Market Capitalization: $563.09 (millions)
Beta: 2.08
52 Week High: $5.97
52 Week Low: $1.11
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -53.44% -47.57%
12 Week -55.49% -51.07%
Year To Date -57.86% -47.79%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
77 Sir John Rogerson`s Quay Block C Grand Canal Docklands
-
Dublin,L2 Dublin 2
IRL
ph: 353-1669-9020
fax: -
investor.relations@amarincorp.com http://www.amarincorp.com
 
 • General Corporate Information   
Officers
Karim Mikhail - Presidentand Chief Executive Officer
Michael W. Kalb - Senior Vice President and Chief Financial Officer
Lars Ekman - Director
Patrick O'Sullivan - Director
Kristine Peterson - Director

Peer Information
Amarin Corporation PLC (CORR.)
Amarin Corporation PLC (RSPI)
Amarin Corporation PLC (CGXP)
Amarin Corporation PLC (BGEN)
Amarin Corporation PLC (GTBP)
Amarin Corporation PLC (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 023111206
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/04/22
Share - Related Items
Shares Outstanding: 396.54
Most Recent Split Date: 1.00 (0.10:1)
Beta: 2.08
Market Capitalization: $563.09 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.06 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.24 Payout Ratio: 0.00
Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/04/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.88
Price/Cash Flow: 23.17
Price / Sales: 1.05
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -300.00%
Sales Growth
vs. Year Ago Period: -33.44%
vs. Previous Quarter: -34.51%
ROE
03/31/22 - -1.31
12/31/21 - 3.31
09/30/21 - 1.89
ROA
03/31/22 - -0.82
12/31/21 - 2.07
09/30/21 - 1.20
Current Ratio
03/31/22 - 2.57
12/31/21 - 2.37
09/30/21 - 2.64
Quick Ratio
03/31/22 - 1.68
12/31/21 - 1.74
09/30/21 - 1.79
Operating Margin
03/31/22 - -1.59
12/31/21 - 3.68
09/30/21 - 1.99
Net Margin
03/31/22 - -4.15
12/31/21 - 1.33
09/30/21 - -0.34
Pre-Tax Margin
03/31/22 - -3.00
12/31/21 - 1.94
09/30/21 - 0.41
Book Value
03/31/22 - 1.62
12/31/21 - 1.68
09/30/21 - 1.62
Inventory Turnover
03/31/22 - 0.43
12/31/21 - 0.46
09/30/21 - 0.50
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©